Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Multi-center, Randomized and Controlled Phase II Trial of Apatinib Mesylate Tablets Combined With PD-1 Antibody SHR-1210 for Adjuvant Treatment of Patients With High Recurrence Risk After Radical Operation of Hepatocellular Carcinoma

Next Previous
Trial Profile

The Multi-center, Randomized and Controlled Phase II Trial of Apatinib Mesylate Tablets Combined With PD-1 Antibody SHR-1210 for Adjuvant Treatment of Patients With High Recurrence Risk After Radical Operation of Hepatocellular Carcinoma

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Mar 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 13 Sep 2022 Results (At date cut off: 4 Mar 2022; n=82) assessing he efficacy and safety of anti-PD-1 antibody SHR-1210 combined with apatinib as adjuvant treatment versus hepatic arterial infusion (HAI) in hepatocellular carcinoma patients with high risk of recurrence after radical resection, presented at the 47th European Society for Medical Oncology Congress.
  • 17 Jan 2021 Status changed from not yet recruiting to recruiting ,as per preliminary results presented at the 2021 Gastrointestinal Cancers Symposium
  • 17 Jan 2021 Preliminary results (n=32) presented at the 2021 Gastrointestinal Cancers Symposium

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top